MET Metlife (MET) Insider Trading, Ownership & Congress Trades
Insurance · Life insurance · CIK 0001099219
Form 144 · 8
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
730
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $984.0K priced
What the filings say about MET
Insiders, 180 days
-$1.7M net sold
1 seller · 0% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2025-08-06
Planned sales (Form 144), 90 days
$118.4K
8 notices
Metlife insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, METLIFE INC insiders sold a net $1.7M of stock across 21 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Dec 13, 2024.
- The trade is 13.8% of the 154,380 shares held after it.
- No other insider sold within 30 days.
- 730 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & Chief Risk Officer DEBEL MARLENE sold about $1.7M of MET on Jun 1, 2026, the largest insider sale at the company since 2025; 730 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Mar 18, 2024.
- The trade is 39.0% of the 66,744 shares held after it.
- No other insider sold within 30 days.
- 730 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Global Tech. & Ops. PAPPAS BILL sold about $2.1M of MET on May 12, 2025, the largest insider sale at the company since 2022; 730 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 9, 2023.
- The trade is 21.0% of the 108,507 shares held after it.
- 1 other insider sold within 30 days.
- 730 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & Chief Risk Officer DEBEL MARLENE sold about $1.9M of MET on Dec 13, 2024; 1 other insider sold within 30 days and 730 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Feb 5, 2024.
- The trade is 4.2% of the 500,799 shares held after it.
- 1 other insider sold within 30 days.
- 730 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Khalaf Michel sold about $1.7M of MET on Dec 13, 2024; 1 other insider sold within 30 days and 730 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Mar 2, 2023.
- The trade is 46.7% of the 57,768 shares held after it.
- 1 other insider sold within 30 days.
- 730 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Global Tech. & Ops. PAPPAS BILL sold about $2.0M of MET on Mar 18, 2024, the largest insider sale at the company since 2022; 1 other insider sold within 30 days and 730 funds added in the latest 13F quarter.21 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.7M over 180 days
more than 58% of Insurance
Congress
no House purchase disclosed in the last 12 months
Funds
730 funds bought in last quarter
more than 92% of Insurance
Revenue
+8.5% year over year
below 54% of Insurance
Margin
138.7% net margin
more than 97% of Insurance
Buybacks
$1.5B repurchased, FY to 2026-06-30
more than 90% of Insurance
Short interest
2.1% of the float short (float per yahoo 2026-10-26) · 3.3 days to cover · settled 2026-09-30
below 77% of Insurance
What changed in the last 30 days
Oct 6Affiliate MetLife Separate Account SPI filed to sell $15.5K by Oct 6 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch MET
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+29.4%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MET: institutional holders (13F)
13F holdings, latest reported quarter
51,786,925 sh
$4.4B
48,431,150 sh
$4.1B
35,483,789 sh
$3.0B
30,031,431 sh
$2.5B
25,336,999 sh
$2.1B
Congress trades in MET
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-08-06 · disclosed 37 days later
$1,001 - $15,000
Sold 2025-07-11 · disclosed 40 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
MET planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
MetLife Separate Account SPI
Filed 2026-10-06
$15.5K
Metlife 401(k) Plan Large Cap Equity Index
Filed 2026-09-18
$25.9K
Separate Account 149
Filed 2026-09-18
$2.4K
Separate Account II
Filed 2026-09-18
$4.4K
MetLife Separate Account SPI
Filed 2026-09-18
$21.8K
MET mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
First Trust Bloomberg Shareholder Yield ETF
$792.0K position · as of 2026-06-30
5.3%
Select Insurance Portfolio
$28.1M position · as of 2026-05-31
4.9%
PGIM Jennison Financial Services Fund
$6.4M position · as of 2026-05-29
4.5%
iShares U.S. Insurance ETF
$17.9M position · as of 2026-06-30
4.2%
Classic Value Fund
$20.4M position · as of 2026-07-31
3.7%
MarketDesk Focused U.S. Momentum ETF
$8.3M position · as of 2026-07-31
3.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Securities And Exchange Commission
SEC SUPPLEMENTAL BENEFITS PLAN (SBP) · 2021-01-01
$38.6M
Securities And Exchange Commission
SUPPLEMENTAL BENEFITS PROGRAM · 2026-01-01
$15.9M
Consumer Financial Protection Bureau
SHORT-TERM AND LONG-TERM DISABILITY INSURANCE SERVICES · 2020-12-18
$6.9M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Metlife Inc. Employees' Political Participation Fund A
Cycle 2026 · $316K spent
$260.1K
Metlife Inc. Employees' Political Participation Fund A - Federal Only
Cycle 2026 · $110K spent
$120.0K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Mr. Khalaf
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$22.4M
$13.8M
$8.0M
+96%
+101%
2024
$20.3M
$30.4M
$7.1M
+98%
+90%
2023
$20.5M
$15.4M
$7.6M
+55%
+58%
2022
$18.1M
$33.0M
$7.5M
+64%
+51%
2021
$16.6M
$32.5M
$6.9M
+37%
+37%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.7M sold by insiders over 180 days, 730 funds added last quarter, $118.4K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
MET financials
Revenue growth
+8.5%
XBRL, annual
Net margin
138.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$79.4B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM MET
| FY Dec 2025 | $77.1B |
| FY Dec 2024 | $71.0B |
| FY Dec 2023 | $66.9B |
| FY Dec 2022 | n/a |
| FY Dec 2021 | $71.1B |
| Jun 2026 | $19.2B |
| Mar 2026 | $19.1B |
| Dec 2025 | $23.8B |
| Sep 2025 | $17.4B |
| Jun 2025 | $17.3B |
| Mar 2025 | $18.6B |
| Dec 2024 | $18.7B |
| Sep 2024 | $18.4B |
At each fiscal year end
Single quarter
Net margin, TTM
+4.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM MET
| FY Dec 2025 | +4.1% |
| FY Dec 2024 | +6.0% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +8.9% |
| Jun 2026 | +3.8% |
| Mar 2026 | +6.2% |
| Dec 2025 | +2.5% |
| Sep 2025 | +5.2% |
| Jun 2025 | +4.2% |
| Mar 2025 | +5.1% |
| Dec 2024 | +5.7% |
| Sep 2024 | +7.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM MET
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.02x
current debt only, 2026-06-30; equity 2026-06-30
Debt to equity MET
| FY Dec 2025 | 0.01x |
| FY Dec 2024 | 0.02x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.01x |
| FY Dec 2021 | 0.01x |
| Jun 2026 | 0.02x |
| Mar 2026 | 0.01x |
| Dec 2025 | 0.01x |
| Sep 2025 | 0.01x |
| Jun 2025 | 0.01x |
| Mar 2025 | 0.01x |
| Dec 2024 | 0.02x |
| Sep 2024 | 0.01x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
33.82x
TTM operating cash flow over current debt only, 2026-06-30
Cash flow to debt MET
| FY Dec 2025 | 48.15x |
| FY Dec 2024 | 31.39x |
| FY Dec 2023 | 115.30x |
| FY Dec 2022 | 74.54x |
| FY Dec 2021 | 36.21x |
| Jun 2026 | 33.82x |
| Mar 2026 | 38.41x |
| Dec 2025 | 48.15x |
| Sep 2025 | 38.70x |
| Jun 2025 | 40.18x |
| Mar 2025 | 43.39x |
| Dec 2024 | 31.39x |
| Sep 2024 | 37.55x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+12.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity MET
| FY Dec 2025 | +11.4% |
| FY Dec 2024 | +14.7% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +8.9% |
| Jun 2026 | +12.4% |
| Mar 2026 | +12.5% |
| Dec 2025 | +11.4% |
| Sep 2025 | +12.2% |
| Jun 2025 | +14.9% |
| Mar 2025 | +15.4% |
| Dec 2024 | +14.7% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+0.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets MET
| FY Dec 2025 | +0.4% |
| FY Dec 2024 | +0.6% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +0.8% |
| Jun 2026 | +0.5% |
| Mar 2026 | +0.5% |
| Dec 2025 | +0.4% |
| Sep 2025 | +0.5% |
| Jun 2025 | +0.6% |
| Mar 2025 | +0.6% |
| Dec 2024 | +0.6% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+67.7%
operating income after a 24.9% effective tax rate, over current debt only, 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital MET
| FY Dec 2025 | +62.0% |
| FY Dec 2024 | +53.6% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +67.7% |
| Mar 2026 | +82.2% |
| Dec 2025 | +62.0% |
| Sep 2025 | +50.2% |
| Jun 2025 | +67.9% |
| Mar 2025 | +58.6% |
| Dec 2024 | +53.6% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
assets or current liabilities not filed
Return on capital employed MET
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
18.93x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing MET
| FY Dec 2025 | 16.80x |
| FY Dec 2024 | 13.74x |
| FY Dec 2023 | 36.14x |
| FY Dec 2022 | 11.49x |
| FY Dec 2021 | 8.14x |
| Jun 2026 | 16.21x |
| Mar 2026 | 13.71x |
| Dec 2025 | 16.80x |
| Sep 2025 | 15.54x |
| Jun 2025 | 13.65x |
| Mar 2025 | 13.08x |
| Dec 2024 | 13.74x |
| Sep 2024 | 16.63x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$44.0B
market value at close 2026-10-23 on 2026-07-31 shares, plus current debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value MET
| FY Dec 2025 | $30.3B |
| FY Dec 2024 | $37.1B |
| FY Dec 2023 | $28.4B |
| FY Dec 2022 | $36.8B |
| FY Dec 2021 | $32.9B |
| Jun 2026 | $35.6B |
| Mar 2026 | $23.8B |
| Dec 2025 | $30.3B |
| Sep 2025 | $34.9B |
| Jun 2025 | $32.2B |
| Mar 2025 | $33.8B |
| Dec 2024 | $37.1B |
| Sep 2024 | $36.4B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield MET
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -11%, PEG needs growth
PEG, trailing MET
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.06x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.23x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 2.27x |
| Jun 2025 | 0.23x |
| Mar 2025 | 0.12x |
| Dec 2024 | 0.06x |
| Sep 2024 | 0.26x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $77.1B | $71.0B | $66.9B | $69.9B |
| Operating income | $6.1B | $6.0B | $5.7B | $6.0B |
| Net income | $3.2B | $4.2B | $1.4B | $2.4B |
| EPS (diluted) | 4.71 | 5.94 | 1.81 | 6.30 |
| Operating cash flow | $17.1B | $14.6B | $13.7B | $13.0B |
| Cash | $22.0B | $20.1B | $20.6B | $20.2B |
| Buybacks | $2.9B | $3.2B | $3.1B | $3.3B |
| Dividends paid | $1.5B | $1.5B | $1.6B | $1.6B |
SEC XBRL, fiscal years, as known on 2026-10-27
MET Stock Sonar score 6/7 axes
Find similar shapesCompareMET ranks highest on financial health (94th percentile) and risk and compliance (61st), and lowest on insider conviction (29th), among Insurance peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MET filings, in plain words
Are Metlife insiders buying or selling MET?
In the 180 days to 2026-10-27, Metlife insiders were net sellers, a net $1.7M across purchases and sales reported on Form 4, by 1 seller.
Have members of Congress traded MET?
Yes, but not in the year to 2026-10-27; the latest on record is a sale by Gilbert Cisneros dated 2025-08-06.
Are there planned insider sales of MET?
Yes. 8 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $118.4K of stock; the latest, by MetLife Separate Account SPI, was filed 2026-10-06.
Read the full summary
In the 180 days to 2026-10-27, Metlife insiders were net sellers of MET, a net $1.7M across purchases and sales reported on Form 4 by 1 seller. Members of Congress have disclosed trades in MET, none in the last year; the latest on record is a sale by Gilbert Cisneros dated 2025-08-06. Insiders filed 8 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $118.4K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
